Product Images Dextrose

This text provides important prescribing information about the temporary importation of various drug products from Alliston, Canada by Baxter Healthcare Corporation to address drug shortages in the United States. The products include 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Lactated Ringer's Injection, and PlasmaLyte A Injection. It mentions that these products have not been approved by the FDA and that only Baxter is authorized to import or distribute them in the United States at that time. It advises healthcare professionals to read all letters provided with the imported products for specific information.*

This text provides information about certain medical products being offered by Baxter during a temporary period. The products listed include descriptions, sizes, product codes, and the number of bags per carton for items such as 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Lactated Ringer's Injection, and PlasmaLyte A Injection. The document suggests that these imported products are available for purchase.*

This text provides important information regarding the differences between imported medical products with 2D barcodes and FDA-approved products in the U.S. It highlights the importance of ensuring correct product identification and administration to patients. The text also mentions incompatibility issues with specific products and emphasizes the need to use a new bag in case of visible particulates or leaks. Additional details are provided in tables comparing the labeling of FDA-approved products and imported products like Sodium Chloride Injection, Dextrose Injection, Lactated Ringer's Injection, and Plasmalyte A Injection.*

This text provides information on how to report adverse events or product quality issues associated with imported products distributed by Baxter. Adverse events can be reported to Baxter directly or through the FDA's MedWatch program via online submission, mail, or fax. Product quality issues can be reported through Baxter's Product Feedback Portal. The text also references specific drug products such as 5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringers Injection.*

This is a comparison table detailing the key differences between an FDA-approved 0.9% Sodium Chloride Injection USP and an imported version from Alksion, Canada. The table includes information such as product name, label volume, language, indications, active ingredients, additional information, storage conditions, container type, medication details, and administration port closures. Key variations in label volume, language, indications, active ingredients, and storage conditions are highlighted for the two products.*

This is a label evaluation of different 0.9% Sodium Chloride Injection products. The labels are meant for US-FDA approved and imported products from Canada. The labels primarily show information for black 1000 mL bottles, but key details like barcode, lot number, and expiry date are not visible. Each label displays the product as "0.9% Sodium Chloride Injection USP", with slight variations in text layout and additional details mentioned in French. The document mentions a "JB1324" code for one of the products. The evaluation is detailed on a single page, marked with the serial number "SHITT-CADHCP 202410021, Rev 00".*

This is a description of a 5% Dextrose Injection, USP used as a source of water and calories. The solution contains 5 grams of Dextrose Hydrous USP in each 100 mL. It provides 10 kcal of caloric content. The osmolarity is 252 mOsmol/L. It is important to store this medication at room temperature. The packaging is described as VIAREX with a medication port and administration port for easy access.*

This text appears to be a comparison between FDA-approved and imported 5% Dextrose Injection USP products. The label images of both products are described, noting that the FDA-approved product is from Alliston, Canada. Details include the label color, size (1000 mL), and missing information such as the barcode, lot number, and expiration date. The text also includes a reference code: SHTT-CADHCP 202410021, Rev 00 Page70f15.*

This is a description of a 5% Dextrose Injection USP in a 1000 mL container manufactured by Baxter. The solution is Dextrose at 5%, USP, Injectable. It is referred to as D5W and has an approximate osmolality of 252 mOsmol/L and a pH of 4.0. The product is indicated for hydration purposes. The document mentions a reference number SHTT-CA-DHCP-202410.021, Rev 00, and indicates that it consists of one page.*

This is a description of an FDA-approved product known as Lactated Ringer's Injection, imported from Alliston, Canada. The product comes in various volumes - 250ml, 500ml, and 1000ml. It is available in English and French languages. Lactated Ringer's Injection is indicated as a source of water, electrolytes, and an alkalizing agent. The active ingredients in each 100ml include Sodium Chloride, Sodium Lactate, Potassium Chloride, and Magnesium Chloride. The solution composition in terms of mEq/l is also provided. It mentions the osmolarity and caloric content. The storage instructions suggest room temperature maintenance. The container type is described as ViarLex (pv). Additionally, details about medication and administration ports are included.*

The text appears to be a description of FDA-approved and imported Lactated Ringer's labels. The labels are compared in terms of their origin, labeling specifications, and product details. Information includes the label color, barcode status, volume shown, product representation, and product composition details. It also mentions the product being an injection, its composition, and various components present in the solution like sodium, potassium, calcium, and lactate. The text ends with a reference number (SHTT-CADHCP 202410021, Rev 00) and a page number (110115). This seems to be a detailed analysis or comparison of Lactated Ringer's products.*

This is a US FDA approved product imported from Alkston, Canada. The product details seem to include components and dosages, possibly related to medication or supplements. The text also mentions indications for use and suggests compatibility with certain conditions or consumer needs. Please refer to the specific product information for accurate details.*

This text appears to be describing a medical device that includes medication ports and administration ports with pull-off features. It seems to be related to the administration of medications, possibly in a healthcare setting. The specific model mentioned is labeled as SHTT-CADHCP 202410021, Rev 00.*

This text provides information about FDA-approved and imported Plasma-Lyte A Injection, USP. It compares the label details of the US-FDA approved product with the imported product from Alliston, Canada. The text includes details like label color, barcode presence, lot number, expiration date, electrolyte content, and container type. It also mentions the manufacturer, Baxter Corporation, located in Mississauga, Canada. This information can be used for reference when identifying and distinguishing between different versions of Plasma-Lyte A Injection in a healthcare setting.*

This is a description of a 5% Dextrose Injection USP used for intravenous fluid and nutrient replenishment. It is a nonpyrogenic, sterile solution provided in a VIAFLEX® PVC container. The pH of the solution is approximately 4.0, with an osmolality of 252 mOsmol/L. It contains Dextrose Hydrous USP, water for injection, and may be adjusted with sodium hydroxide. The solution should be discarded after single use and should not be used in series connections. It should not be administered simultaneously with blood and should be stored between 15°C and 25°C. The product is manufactured by Baxter Corporation in Mississauga, ON.*

This text provides information on a 1000 mL bag of 5% Dextrose Injection USP, also known as D5W. It includes details on the osmolality, pH level, instructions for use, precautions, storage conditions, and the manufacturer Baxter. The product is described as nonpyrogenic, sterile, and intended for single use. It also specifies that it should not be used in series connections or simultaneously with blood. The text mentions that the pH level can be adjusted with sodium hydroxide.*